Global Heart Failure Therapeutics - Market

Heart Failure Therapeutics - Comprehensive Study by Type (Diagnosis, Prognosis), Application (Hospital, Clinic, Medical Research Organization) Players and Region - Global Market Outlook to 2030

Heart Failure Therapeutics - Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Heart Failure Therapeutics -
Heart diseases are growing exponentially because of the rapidly changing lifestyle and increasing stress levels. This is driving the heart failure therapeutics market worldwide. This critically important market will further grow owing to increased expenditure on healthcare and reimbursement policies. Continuous Research and developments in these devices and procedures are encouraging patients to adapt to these therapies.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Heart Failure Therapeutics market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Heart Failure Therapeutics Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Heart Failure Therapeutics - market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Medtronic (United States), St. Jude Medical (United States), Boston Scientific (United States), Edwards Lifesciences (United States), Abbott Laboratories (United States), Johnson & Johnson (United States), Getinge (Sweden), Terumo (Japan), Pfizer Inc. (United States) and Novartis AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Hengrui Medicine (China), Cardio3 BioSciences (Belgium), Sigma-Tau Gamma (United States), Takeda (Japan), W. L. Gore & Associates (United States), Lepu Medical Technology (China), Bayer AG (Germany), Cynokinetics (United States), Servier (France), Merck & Co., Inc. (United States), Cardiorentis AG (Switzerland), Orion Corporation (Finland) and PhaseBio Pharmaceuticals (United States).

Segmentation Overview
AMA Research has segmented the market of Global Heart Failure Therapeutics - market by Type (Diagnosis and Prognosis), Application (Hospital, Clinic and Medical Research Organization) and Region.



On the basis of geography, the market of Heart Failure Therapeutics - has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Devices Developed To Reduced Overall Skin Pressure are Gaining Popularity and Implants with Rate Adaptive Pacing are Trending

Market Growth Drivers:
Increased Prevalence of Chronic Heart Failure and Incidence of Acute Heart Failure Worldwide and The Success of Various Heart Failure Therapies in Reducing Mortality and Morbidity

Challenges:
Highly Mature Market Makes It Difficult To Penetrate

Restraints:
Fear of Late Complications and Reimbursement Issues and High Pricing and the Reluctance of Cardiologists and Physicians to Adopt New Therapies

Opportunities:
Potential Market Growth in Countries with the Highest Rate of Degenerative Diseases Such As Diabetes and Increasing Affordability and Healthcare Access in Developing Countries

Market Leaders and their expansionary development strategies
Medtronic, a global leader in medical technology, and Viz.ai, the emerging leader in applied artificial intelligence (AI) in stroke care, have partnered to accelerate the adoption of Viz.ai’s new technology, which helps synchronize stroke care and decrease time to treatment, potentially improving outcomes for patients. Viz.ai’s technology uses artificial intelligence to identify suspected large vessel occlusion (LVO) strokes and automatically notify specialists.
Implantable Pulse Generators (IPGs) by Medtronic are indicated for rate-adaptive pacing in patients who may benefit from increased pacing rates concurrent with increases in activity. Pacemakers are also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for the treatment of conduction disorders that require restoration of both rate and AV synchrony.
European manufacturers such digital health technologies, medical applications and wearable body sensors as examples, must carefully consider the new rules and regulatory requirements set forth within the Medical Devices Regulation (MDR), adopted by the European Parliament and Council in May 2017. The new EU MDR, with a mandatory compliance date of 26 May 2020, replaces the former Medical Device Directive (MDD) and introduces new concepts, definitions, classification rules and procedural requirements for medical device software – and particularly for software products currently regulated as Class I medical devices in Europe. Many digital health technologies will now fall into the scope of the new European MDR. Manufacturers of digital health applications must carefully examine new MDR requirements for CE-marked technologies prior to commercial distribution to determine where they may fall into the definition of ‘medical device’ within the new EU regulation.

Key Target Audience
Keyword Manufacturer, Distributor and Supplier, Healthcare Industry, Government Bodies and Associations, Raw Material Supplier, Research Companies and End-User

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Diagnosis
  • Prognosis
By Application
  • Hospital
  • Clinic
  • Medical Research Organization
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Chronic Heart Failure and Incidence of Acute Heart Failure Worldwide
      • 3.2.2. The Success of Various Heart Failure Therapies in Reducing Mortality and Morbidity
    • 3.3. Market Challenges
      • 3.3.1. Highly Mature Market Makes It Difficult To Penetrate
    • 3.4. Market Trends
      • 3.4.1. Devices Developed To Reduced Overall Skin Pressure are Gaining Popularity
      • 3.4.2. Implants with Rate Adaptive Pacing are Trending
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Heart Failure Therapeutics -, by Type, Application and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Heart Failure Therapeutics - (Value)
      • 5.2.1. Global Heart Failure Therapeutics - by: Type (Value)
        • 5.2.1.1. Diagnosis
        • 5.2.1.2. Prognosis
      • 5.2.2. Global Heart Failure Therapeutics - by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Medical Research Organization
      • 5.2.3. Global Heart Failure Therapeutics - Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Heart Failure Therapeutics - (Volume)
      • 5.3.1. Global Heart Failure Therapeutics - by: Type (Volume)
        • 5.3.1.1. Diagnosis
        • 5.3.1.2. Prognosis
      • 5.3.2. Global Heart Failure Therapeutics - by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinic
        • 5.3.2.3. Medical Research Organization
      • 5.3.3. Global Heart Failure Therapeutics - Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Heart Failure Therapeutics - (Price)
      • 5.4.1. Global Heart Failure Therapeutics - by: Type (Price)
  • 6. Heart Failure Therapeutics -: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Medtronic (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. St. Jude Medical (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boston Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Edwards Lifesciences (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Getinge (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Terumo (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Heart Failure Therapeutics - Sale, by Type, Application and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Heart Failure Therapeutics - (Value)
      • 7.2.1. Global Heart Failure Therapeutics - by: Type (Value)
        • 7.2.1.1. Diagnosis
        • 7.2.1.2. Prognosis
      • 7.2.2. Global Heart Failure Therapeutics - by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Medical Research Organization
      • 7.2.3. Global Heart Failure Therapeutics - Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Heart Failure Therapeutics - (Volume)
      • 7.3.1. Global Heart Failure Therapeutics - by: Type (Volume)
        • 7.3.1.1. Diagnosis
        • 7.3.1.2. Prognosis
      • 7.3.2. Global Heart Failure Therapeutics - by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinic
        • 7.3.2.3. Medical Research Organization
      • 7.3.3. Global Heart Failure Therapeutics - Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Heart Failure Therapeutics - (Price)
      • 7.4.1. Global Heart Failure Therapeutics - by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Heart Failure Therapeutics -: by Type(USD Million)
  • Table 2. Heart Failure Therapeutics - Diagnosis , by Region USD Million (2018-2023)
  • Table 3. Heart Failure Therapeutics - Prognosis , by Region USD Million (2018-2023)
  • Table 4. Heart Failure Therapeutics -: by Application(USD Million)
  • Table 5. Heart Failure Therapeutics - Hospital , by Region USD Million (2018-2023)
  • Table 6. Heart Failure Therapeutics - Clinic , by Region USD Million (2018-2023)
  • Table 7. Heart Failure Therapeutics - Medical Research Organization , by Region USD Million (2018-2023)
  • Table 8. South America Heart Failure Therapeutics -, by Country USD Million (2018-2023)
  • Table 9. South America Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 10. South America Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 11. Brazil Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 12. Brazil Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 13. Argentina Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 14. Argentina Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 15. Rest of South America Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 16. Rest of South America Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 17. Asia Pacific Heart Failure Therapeutics -, by Country USD Million (2018-2023)
  • Table 18. Asia Pacific Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 19. Asia Pacific Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 20. China Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 21. China Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 22. Japan Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 23. Japan Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 24. India Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 25. India Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 26. South Korea Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 27. South Korea Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 28. Taiwan Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 29. Taiwan Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 30. Australia Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 31. Australia Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 32. Rest of Asia-Pacific Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 33. Rest of Asia-Pacific Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 34. Europe Heart Failure Therapeutics -, by Country USD Million (2018-2023)
  • Table 35. Europe Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 36. Europe Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 37. Germany Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 38. Germany Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 39. France Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 40. France Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 41. Italy Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 42. Italy Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 43. United Kingdom Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 44. United Kingdom Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 45. Netherlands Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 46. Netherlands Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 47. Rest of Europe Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 48. Rest of Europe Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 49. MEA Heart Failure Therapeutics -, by Country USD Million (2018-2023)
  • Table 50. MEA Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 51. MEA Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 52. Middle East Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 53. Middle East Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 54. Africa Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 55. Africa Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 56. North America Heart Failure Therapeutics -, by Country USD Million (2018-2023)
  • Table 57. North America Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 58. North America Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 59. United States Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 60. United States Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 61. Canada Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 62. Canada Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 63. Mexico Heart Failure Therapeutics -, by Type USD Million (2018-2023)
  • Table 64. Mexico Heart Failure Therapeutics -, by Application USD Million (2018-2023)
  • Table 65. Heart Failure Therapeutics - Sales: by Type(K Units)
  • Table 66. Heart Failure Therapeutics - Sales Diagnosis , by Region K Units (2018-2023)
  • Table 67. Heart Failure Therapeutics - Sales Prognosis , by Region K Units (2018-2023)
  • Table 68. Heart Failure Therapeutics - Sales: by Application(K Units)
  • Table 69. Heart Failure Therapeutics - Sales Hospital , by Region K Units (2018-2023)
  • Table 70. Heart Failure Therapeutics - Sales Clinic , by Region K Units (2018-2023)
  • Table 71. Heart Failure Therapeutics - Sales Medical Research Organization , by Region K Units (2018-2023)
  • Table 72. South America Heart Failure Therapeutics - Sales, by Country K Units (2018-2023)
  • Table 73. South America Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 74. South America Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 75. Brazil Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 76. Brazil Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 77. Argentina Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 78. Argentina Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 79. Rest of South America Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 80. Rest of South America Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 81. Asia Pacific Heart Failure Therapeutics - Sales, by Country K Units (2018-2023)
  • Table 82. Asia Pacific Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 83. Asia Pacific Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 84. China Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 85. China Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 86. Japan Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 87. Japan Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 88. India Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 89. India Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 90. South Korea Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 91. South Korea Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 92. Taiwan Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 93. Taiwan Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 94. Australia Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 95. Australia Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 96. Rest of Asia-Pacific Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 97. Rest of Asia-Pacific Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 98. Europe Heart Failure Therapeutics - Sales, by Country K Units (2018-2023)
  • Table 99. Europe Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 100. Europe Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 101. Germany Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 102. Germany Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 103. France Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 104. France Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 105. Italy Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 106. Italy Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 107. United Kingdom Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 108. United Kingdom Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 109. Netherlands Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 110. Netherlands Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 111. Rest of Europe Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 112. Rest of Europe Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 113. MEA Heart Failure Therapeutics - Sales, by Country K Units (2018-2023)
  • Table 114. MEA Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 115. MEA Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 116. Middle East Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 117. Middle East Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 118. Africa Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 119. Africa Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 120. North America Heart Failure Therapeutics - Sales, by Country K Units (2018-2023)
  • Table 121. North America Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 122. North America Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 123. United States Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 124. United States Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 125. Canada Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 126. Canada Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 127. Mexico Heart Failure Therapeutics - Sales, by Type K Units (2018-2023)
  • Table 128. Mexico Heart Failure Therapeutics - Sales, by Application K Units (2018-2023)
  • Table 129. Heart Failure Therapeutics -: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Heart Failure Therapeutics -: by Type(USD Million)
  • Table 141. Heart Failure Therapeutics - Diagnosis , by Region USD Million (2025-2030)
  • Table 142. Heart Failure Therapeutics - Prognosis , by Region USD Million (2025-2030)
  • Table 143. Heart Failure Therapeutics -: by Application(USD Million)
  • Table 144. Heart Failure Therapeutics - Hospital , by Region USD Million (2025-2030)
  • Table 145. Heart Failure Therapeutics - Clinic , by Region USD Million (2025-2030)
  • Table 146. Heart Failure Therapeutics - Medical Research Organization , by Region USD Million (2025-2030)
  • Table 147. South America Heart Failure Therapeutics -, by Country USD Million (2025-2030)
  • Table 148. South America Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 149. South America Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 150. Brazil Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 151. Brazil Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 152. Argentina Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 153. Argentina Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 154. Rest of South America Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 155. Rest of South America Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 156. Asia Pacific Heart Failure Therapeutics -, by Country USD Million (2025-2030)
  • Table 157. Asia Pacific Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 158. Asia Pacific Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 159. China Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 160. China Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 161. Japan Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 162. Japan Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 163. India Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 164. India Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 165. South Korea Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 166. South Korea Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 167. Taiwan Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 168. Taiwan Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 169. Australia Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 170. Australia Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 171. Rest of Asia-Pacific Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 172. Rest of Asia-Pacific Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 173. Europe Heart Failure Therapeutics -, by Country USD Million (2025-2030)
  • Table 174. Europe Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 175. Europe Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 176. Germany Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 177. Germany Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 178. France Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 179. France Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 180. Italy Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 181. Italy Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 182. United Kingdom Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 183. United Kingdom Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 184. Netherlands Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 185. Netherlands Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 186. Rest of Europe Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 187. Rest of Europe Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 188. MEA Heart Failure Therapeutics -, by Country USD Million (2025-2030)
  • Table 189. MEA Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 190. MEA Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 191. Middle East Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 192. Middle East Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 193. Africa Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 194. Africa Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 195. North America Heart Failure Therapeutics -, by Country USD Million (2025-2030)
  • Table 196. North America Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 197. North America Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 198. United States Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 199. United States Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 200. Canada Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 201. Canada Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 202. Mexico Heart Failure Therapeutics -, by Type USD Million (2025-2030)
  • Table 203. Mexico Heart Failure Therapeutics -, by Application USD Million (2025-2030)
  • Table 204. Heart Failure Therapeutics - Sales: by Type(K Units)
  • Table 205. Heart Failure Therapeutics - Sales Diagnosis , by Region K Units (2025-2030)
  • Table 206. Heart Failure Therapeutics - Sales Prognosis , by Region K Units (2025-2030)
  • Table 207. Heart Failure Therapeutics - Sales: by Application(K Units)
  • Table 208. Heart Failure Therapeutics - Sales Hospital , by Region K Units (2025-2030)
  • Table 209. Heart Failure Therapeutics - Sales Clinic , by Region K Units (2025-2030)
  • Table 210. Heart Failure Therapeutics - Sales Medical Research Organization , by Region K Units (2025-2030)
  • Table 211. South America Heart Failure Therapeutics - Sales, by Country K Units (2025-2030)
  • Table 212. South America Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 213. South America Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 214. Brazil Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 215. Brazil Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 216. Argentina Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 217. Argentina Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 218. Rest of South America Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 219. Rest of South America Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 220. Asia Pacific Heart Failure Therapeutics - Sales, by Country K Units (2025-2030)
  • Table 221. Asia Pacific Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 222. Asia Pacific Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 223. China Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 224. China Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 225. Japan Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 226. Japan Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 227. India Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 228. India Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 229. South Korea Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 230. South Korea Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 231. Taiwan Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 232. Taiwan Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 233. Australia Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 234. Australia Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 235. Rest of Asia-Pacific Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 236. Rest of Asia-Pacific Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 237. Europe Heart Failure Therapeutics - Sales, by Country K Units (2025-2030)
  • Table 238. Europe Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 239. Europe Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 240. Germany Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 241. Germany Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 242. France Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 243. France Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 244. Italy Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 245. Italy Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 246. United Kingdom Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 247. United Kingdom Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 248. Netherlands Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 249. Netherlands Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 250. Rest of Europe Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 251. Rest of Europe Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 252. MEA Heart Failure Therapeutics - Sales, by Country K Units (2025-2030)
  • Table 253. MEA Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 254. MEA Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 255. Middle East Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 256. Middle East Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 257. Africa Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 258. Africa Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 259. North America Heart Failure Therapeutics - Sales, by Country K Units (2025-2030)
  • Table 260. North America Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 261. North America Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 262. United States Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 263. United States Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 264. Canada Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 265. Canada Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 266. Mexico Heart Failure Therapeutics - Sales, by Type K Units (2025-2030)
  • Table 267. Mexico Heart Failure Therapeutics - Sales, by Application K Units (2025-2030)
  • Table 268. Heart Failure Therapeutics -: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Heart Failure Therapeutics -: by Type USD Million (2018-2023)
  • Figure 5. Global Heart Failure Therapeutics -: by Application USD Million (2018-2023)
  • Figure 6. South America Heart Failure Therapeutics - Share (%), by Country
  • Figure 7. Asia Pacific Heart Failure Therapeutics - Share (%), by Country
  • Figure 8. Europe Heart Failure Therapeutics - Share (%), by Country
  • Figure 9. MEA Heart Failure Therapeutics - Share (%), by Country
  • Figure 10. North America Heart Failure Therapeutics - Share (%), by Country
  • Figure 11. Global Heart Failure Therapeutics -: by Type K Units (2018-2023)
  • Figure 12. Global Heart Failure Therapeutics -: by Application K Units (2018-2023)
  • Figure 13. South America Heart Failure Therapeutics - Share (%), by Country
  • Figure 14. Asia Pacific Heart Failure Therapeutics - Share (%), by Country
  • Figure 15. Europe Heart Failure Therapeutics - Share (%), by Country
  • Figure 16. MEA Heart Failure Therapeutics - Share (%), by Country
  • Figure 17. North America Heart Failure Therapeutics - Share (%), by Country
  • Figure 18. Global Heart Failure Therapeutics -: by Type USD/Units (2018-2023)
  • Figure 19. Global Heart Failure Therapeutics - share by Players 2023 (%)
  • Figure 20. Global Heart Failure Therapeutics - share by Players (Top 3) 2023(%)
  • Figure 21. Global Heart Failure Therapeutics - share by Players (Top 5) 2023(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Medtronic (United States) Revenue, Net Income and Gross profit
  • Figure 24. Medtronic (United States) Revenue: by Geography 2023
  • Figure 25. St. Jude Medical (United States) Revenue, Net Income and Gross profit
  • Figure 26. St. Jude Medical (United States) Revenue: by Geography 2023
  • Figure 27. Boston Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 28. Boston Scientific (United States) Revenue: by Geography 2023
  • Figure 29. Edwards Lifesciences (United States) Revenue, Net Income and Gross profit
  • Figure 30. Edwards Lifesciences (United States) Revenue: by Geography 2023
  • Figure 31. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 32. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 33. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 34. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 35. Getinge (Sweden) Revenue, Net Income and Gross profit
  • Figure 36. Getinge (Sweden) Revenue: by Geography 2023
  • Figure 37. Terumo (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Terumo (Japan) Revenue: by Geography 2023
  • Figure 39. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 43. Global Heart Failure Therapeutics -: by Type USD Million (2025-2030)
  • Figure 44. Global Heart Failure Therapeutics -: by Application USD Million (2025-2030)
  • Figure 45. South America Heart Failure Therapeutics - Share (%), by Country
  • Figure 46. Asia Pacific Heart Failure Therapeutics - Share (%), by Country
  • Figure 47. Europe Heart Failure Therapeutics - Share (%), by Country
  • Figure 48. MEA Heart Failure Therapeutics - Share (%), by Country
  • Figure 49. North America Heart Failure Therapeutics - Share (%), by Country
  • Figure 50. Global Heart Failure Therapeutics -: by Type K Units (2025-2030)
  • Figure 51. Global Heart Failure Therapeutics -: by Application K Units (2025-2030)
  • Figure 52. South America Heart Failure Therapeutics - Share (%), by Country
  • Figure 53. Asia Pacific Heart Failure Therapeutics - Share (%), by Country
  • Figure 54. Europe Heart Failure Therapeutics - Share (%), by Country
  • Figure 55. MEA Heart Failure Therapeutics - Share (%), by Country
  • Figure 56. North America Heart Failure Therapeutics - Share (%), by Country
  • Figure 57. Global Heart Failure Therapeutics -: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Medtronic (United States)
  • St. Jude Medical (United States)
  • Boston Scientific (United States)
  • Edwards Lifesciences (United States)
  • Abbott Laboratories (United States)
  • Johnson & Johnson (United States)
  • Getinge (Sweden)
  • Terumo (Japan)
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
Additional players considered in the study are as follows:
Hengrui Medicine (China) , Cardio3 BioSciences (Belgium) , Sigma-Tau Gamma (United States) , Takeda (Japan) , W. L. Gore & Associates (United States) , Lepu Medical Technology (China) , Bayer AG (Germany) , Cynokinetics (United States) , Servier (France) , Merck & Co., Inc. (United States) , Cardiorentis AG (Switzerland) , Orion Corporation (Finland) , PhaseBio Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 212 Pages 51 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Heart Failure Therapeutics - Market Quantitative research analysis
Global Heart Failure Therapeutics - Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Medtronic (United States), St. Jude Medical (United States), Boston Scientific (United States), Edwards Lifesciences (United States), Abbott Laboratories (United States), Johnson & Johnson (United States), Getinge (Sweden), Terumo (Japan), Pfizer Inc. (United States) and Novartis AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Devices Developed To Reduced Overall Skin Pressure are Gaining Popularity " is seen as one of major influencing trends for Heart Failure Therapeutics - Market during projected period 2023-2030.
The Heart Failure Therapeutics - market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Heart Failure Therapeutics - Market Report?

Have a Query? Click Here

Other Related Reports

Oligodendroglioma Treatment Comprehensive Study by Treatment Type Names (Surgery, Radiotherapy, Chemotherapy), Type of Oligodendroglioma (Pure Oligodendroglioma, Mixed Oligodendroglioma), Grade Type ...
$ 3350
Cervical Cancer Comprehensive Study by Type (Squamous cell carcinoma, Adenocarcinoma), Application (Hospitals, Cancer Palliative care clinics, Diagnostic centers, Pharmacies), Drug Type (Avastin (Bev...
$ 3750
Wound Care Treatments Comprehensive Study by Type (Surgical Wound Care Products, Advanced Wound Care Products, Traditional Wound Care Products), Application (Hospitals, Clinics, Home Care, Others), W...
$ 3350
Tinnitus Management Comprehensive Study by Type (Sound Masking Devices, Hearing Aids, Notched Music Devices, Cochlear Implant), Indication (Subjective Tinnitus, Objective Tinnitus), Distribution Chan...
$ 3450
Dravet Syndrome Treatment Comprehensive Study by Type (Clobazam (CLB in some regions),, As initial therapy,, Stiripentol (STP),, Cannabidiol (CBD), Or fenfluramine (FFA) as escalation therapies;), Ap...
$ 3650
Infectious Disease Treatment Comprehensive Study by Application (Humans, Animals), Treatment (Antibiotics, Antivirals, Antifungals, Anti-parasitics), Cause (Viruses, Bacteria, Fungi, Parasites), Diag...
$ 3650